Your browser doesn't support javascript.
loading
Improvement of the Ocular Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A National Survey in Japan.
Kojima, Miho; Mieno, Hiroki; Ueta, Mayumi; Nakata, Mitsuko; Teramukai, Satoshi; Sunaga, Yuma; Ochiai, Hirotaka; Iijima, Masafumi; Kokaze, Akatsuki; Watanabe, Hideaki; Kurosawa, Michiko; Azukizawa, Hiroaki; Asada, Hideo; Watanabe, Yuko; Yamaguchi, Yukie; Aihara, Michiko; Ikezawa, Zenro; Mizukawa, Yoshiko; Ohyama, Manabu; Shiohara, Tetsuo; Hama, Natsumi; Abe, Riichiro; Hashizume, Hideo; Nakajima, Saeko; Nomura, Takashi; Kabashima, Kenji; Tohyama, Mikiko; Hashimoto, Koji; Takahashi, Hayato; Niihara, Hiroyuki; Morita, Eishin; Sueki, Hirohiko; Kinoshita, Shigeru; Sotozono, Chie.
Afiliação
  • Kojima M; From the Department of Ophthalmology, Kyoto Prefectural University of Medicine (M.Ko., H.M., M.U., C.S.), Kyoto, Japan.
  • Mieno H; From the Department of Ophthalmology, Kyoto Prefectural University of Medicine (M.Ko., H.M., M.U., C.S.), Kyoto, Japan.
  • Ueta M; From the Department of Ophthalmology, Kyoto Prefectural University of Medicine (M.Ko., H.M., M.U., C.S.), Kyoto, Japan.
  • Nakata M; Department of Biostatistics, Kyoto Prefectural University of Medicine (M.N., K.F., S.T.), Kyoto, Japan.
  • Teramukai S; Department of Biostatistics, Kyoto Prefectural University of Medicine (M.N., K.F., S.T.), Kyoto, Japan.
  • Sunaga Y; Department of Dermatology, Showa University School of Medicine (Y.S., M.I., H.W., H.S.), Tokyo, Japan; Department of Hygiene, Public Health, and Preventive Medicine, Showa University School of Medicine (Y.S., H.O., A.K.), Tokyo, Japan.
  • Ochiai H; Department of Hygiene, Public Health, and Preventive Medicine, Showa University School of Medicine (Y.S., H.O., A.K.), Tokyo, Japan.
  • Iijima M; Department of Dermatology, Showa University School of Medicine (Y.S., M.I., H.W., H.S.), Tokyo, Japan.
  • Kokaze A; Department of Hygiene, Public Health, and Preventive Medicine, Showa University School of Medicine (Y.S., H.O., A.K.), Tokyo, Japan.
  • Watanabe H; Department of Dermatology, Showa University School of Medicine (Y.S., M.I., H.W., H.S.), Tokyo, Japan; Department of Dermatology, Showa University Northern Yokohama Hospital (H.W.), Yokohama, Japan.
  • Kurosawa M; Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine (M.Ku.), Tokyo, Japan.
  • Azukizawa H; Department of Dermatology, Nara Medical University (H.Az., H.As.), Nara, Japan.
  • Asada H; Department of Dermatology, Nara Medical University (H.Az., H.As.), Nara, Japan.
  • Watanabe Y; Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine (Y.W., Y.Y., M.A., Z.I.), Yokohama, Japan.
  • Yamaguchi Y; Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine (Y.W., Y.Y., M.A., Z.I.), Yokohama, Japan.
  • Aihara M; Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine (Y.W., Y.Y., M.A., Z.I.), Yokohama, Japan.
  • Ikezawa Z; Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine (Y.W., Y.Y., M.A., Z.I.), Yokohama, Japan.
  • Mizukawa Y; Department of Dermatology, Kyorin University Faculty of Medicine (Y.M., M.O., T.S.), Tokyo, Japan.
  • Ohyama M; Department of Dermatology, Kyorin University Faculty of Medicine (Y.M., M.O., T.S.), Tokyo, Japan.
  • Shiohara T; Department of Dermatology, Kyorin University Faculty of Medicine (Y.M., M.O., T.S.), Tokyo, Japan.
  • Hama N; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences (N.H., R.A.), Niigata, Japan.
  • Abe R; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences (N.H., R.A.), Niigata, Japan.
  • Hashizume H; Department of Dermatology, Iwata City Hospital (H.H.), Iwata, Japan.
  • Nakajima S; Department of Dermatology, Kyoto University (S.N., T.N., K.K.), Kyoto, Japan.
  • Nomura T; Department of Dermatology, Kyoto University (S.N., T.N., K.K.), Kyoto, Japan.
  • Kabashima K; Department of Dermatology, Kyoto University (S.N., T.N., K.K.), Kyoto, Japan.
  • Tohyama M; Department of Dermatology, National Hospital Organization Shikoku Cancer Center (M.T., K.H.), Matsuyama, Japan.
  • Hashimoto K; Department of Dermatology, National Hospital Organization Shikoku Cancer Center (M.T., K.H.), Matsuyama, Japan.
  • Takahashi H; Department of Dermatology, Keio University School of Medicine (H.T.), Tokyo, Japan.
  • Niihara H; Department of Dermatology, Shimane University Faculty of Medicine (H.N., E.M.), Matsue, Japan.
  • Morita E; Department of Dermatology, Shimane University Faculty of Medicine (H.N., E.M.), Matsue, Japan.
  • Sueki H; Department of Dermatology, Showa University School of Medicine (Y.S., M.I., H.W., H.S.), Tokyo, Japan.
  • Kinoshita S; Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine (S.K.), Kyoto, Japan.
  • Sotozono C; From the Department of Ophthalmology, Kyoto Prefectural University of Medicine (M.Ko., H.M., M.U., C.S.), Kyoto, Japan. Electronic address: csotozon@koto.kpu-m.ac.jp.
Am J Ophthalmol ; 267: 50-60, 2024 May 24.
Article em En | MEDLINE | ID: mdl-38795750
ABSTRACT

PURPOSE:

To investigate the incidence and prognostic factors of ocular sequelae in Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) cases arising between 2016 and 2018 in Japan, and compare the findings with those presented in the previous 2005-2007 survey.

DESIGN:

Retrospective, national trend survey.

METHODS:

Dermatologic case report forms (CRFs) (d-CRFs) were sent to 257 institutions that treated at least 1 SJS/TEN case, and 508 CRFs were collected from 160 institutions. Ophthalmologic CRFs (o-CRFs) regarding patient demographic data, onset date, ocular findings (first appearance, day of worst severity, and final follow-up), topical treatment (betamethasone), outcome (survival or death), and ocular sequelae (visual disturbance, eye dryness) were sent to the ophthalmologists in those 160 institutions. The results of this survey were then compared with that of the previous 2005-2007 survey.

RESULTS:

A total of 240 cases (SJS/TEN 132/108) were included. The incidence of ocular sequelae incidence was 14.0%, a significant decrease from the 39.2% in the previous survey (SJS/TEN 87/48). In 197 (82.1%) of the cases, systemic treatment was initiated within 3 days after admission, an increase compared to the previous survey (ie, treatment initiated in 82 [60.7%] of 135 cases). Of the 85 cases with an Acute Ocular Severity Score of 2 and 3, 62 (72.9%) received corticosteroid pulse therapy and 73 (85.9%) received 0.1% betamethasone therapy; an increase compared to the 60.0% and 70.8%, respectively, in the previous survey. Ocular-sequelae-associated risk factors included Acute Ocular Severity Score (P < .001) and specific year in the survey (P < .001).

CONCLUSIONS:

The ophthalmologic prognosis of SJS/TEN has dramatically improved via early diagnosis, rapid assessment of acute ocular severity, and early treatment.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article